← Scroll for more →
Gilead Sciences, Inc. (GILD)
Biological Products, (No Diagnostic Substances)
Latest Price
$170.68
TTM P/E
--
Normalized P/E
79.76
TTM Div Yield
1.90%
Fwd Div Yield
1.92%
Book Value
10.52
P/B Ratio
16.23
Valuation metrics
adjust assumptions →EPS: $6.78
Book value / share: $18.29
Formula: √(22.5 × EPS × BVPS)
Graham Number
$52.83
69% downside
Norm. op. income: $7.3B (median of 7yr)
Tax rate: 21%
Discount rate: 10%
Growth assumption: zero (EPV is a no-growth value)
Earnings Power Value
$30.18
82% downside
Base FCF: $9.5B (median of recent 5yr)
Growth: -9%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$31.86
81% downside
EPS: $6.78
Target P/E: 80×
Formula: EPS × P/E
P/E Fair Value
$542.40
+218% upside
Institutional Ownership
89.5% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 121.84M | $15.39B | 9.82% | +2.83M | 2026-06-30 |
| Vanguard Capital Management LLC | 81.09M | $10.24B | 6.53% | +437.0K | 2026-06-30 |
| FMR LLC | 66.87M | $8.45B | 5.39% | -5.04M | 2026-06-30 |
| State Street Corp | 61.22M | $7.73B | 4.93% | +1.36M | 2026-06-30 |
| Capital World Investors | 40.99M | $5.18B | 3.30% | -295.0K | 2026-06-30 |
| Invesco Ltd. | 39.82M | $5.03B | 3.21% | +24.29M | 2026-06-30 |
| Vanguard Portfolio Management LLC | 35.32M | $4.46B | 2.85% | +186.7K | 2026-06-30 |
| Geode Capital Management, LLC | 30.07M | $3.79B | 2.42% | +339.6K | 2026-06-30 |
| Price T Rowe Associates Inc | 30.00M | $3.79B | 2.42% | +3.75M | 2026-06-30 |
| Morgan Stanley | 24.00M | $3.03B | 1.93% | +705.1K | 2026-06-30 |